Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome.

Journal Article

Here we present, to the best of our knowledge, the first case of a paraneoplastic Cushing's syndrome (hypercortisolism) resulting from treatment-related neuroendocrine prostate cancer - a highly aggressive and difficult disease to treat. A 51-year-old man was started on androgen deprivation therapy after presenting with metastatic prostate cancer, characterized by diffuse osseous metastasis. Shortly thereafter, he developed progressive disease with biopsy proven neuroendocrine prostate cancer as well as symptoms of increased skin pigmentation, hypokalemia, hypertension, hyperglycemia and profound weakness, consistent with ectopic Cushing's syndrome. Molecular analysis of the patient's tumor through RNA sequencing showed high expression of several genes including CHGA, ASCL1, CALCA, HES6, PCSK1, CALCB and INSM1 confirming his neuroendocrine phenotype; elevated POMC expression was found, supporting the diagnosis of ectopic Cushing's syndrome.

Full Text

Duke Authors

Cited Authors

  • Ramalingam, S; Eisenberg, A; Foo, WC; Freedman, J; Armstrong, AJ; Moss, LG; Harrison, MR

Published Date

  • December 2016

Published In

Volume / Issue

  • 23 / 12

Start / End Page

  • 1038 - 1041

PubMed ID

  • 27766686

Electronic International Standard Serial Number (EISSN)

  • 1442-2042

Digital Object Identifier (DOI)

  • 10.1111/iju.13225


  • eng

Conference Location

  • Australia